Smithbridge Asset Management Inc. DE Has $2.76 Million Stake in Edwards Lifesciences Corporation $EW

Smithbridge Asset Management Inc. DE boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 106.2% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 32,398 shares of the medical research company’s stock after purchasing an additional 16,688 shares during the period. Smithbridge Asset Management Inc. DE’s holdings in Edwards Lifesciences were worth $2,762,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of EW. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter valued at $25,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $28,000. Hilton Head Capital Partners LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $28,000. Hantz Financial Services Inc. raised its holdings in shares of Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the period. Finally, Dorato Capital Management acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 620 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at $3,278,948.54. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 81,038 shares of company stock valued at $6,683,255. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Trading Down 1.8%

NYSE:EW opened at $85.95 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a 50-day moving average of $82.58 and a 200-day moving average of $83.09. The company has a market cap of $49.49 billion, a PE ratio of 45.72, a PEG ratio of 2.20 and a beta of 0.87. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $89.48.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on EW shares. Piper Sandler reiterated an “overweight” rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a report on Wednesday, April 1st. BTIG Research upped their price objective on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a report on Friday, April 24th. Finally, TD Cowen reiterated a “buy” rating and set a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.